^
    2d
    Mannosylated graphene oxide nanotherapeutics co-delivering docetaxel and a STING agonist reprogram myeloid cells and potentiate antitumor immunity. (PubMed, Mater Today Bio)
    Docetaxel and vadimezan (DMXAA), a prototypical STING agonist, were co-loaded into GO-EDM to generate GO-EDM-DTX-Vad. Taken together, GO-EDM-DTX-Vad leverages passive tumor accumulation and mannose receptor-guided dual targeting of TAMs and TIDCs to integrate DTX-based chemotherapy, STING-mediated immune activation and mild NIR photothermal therapy. This integrated chemo-photothermal-immunotherapeutic design couples direct tumor cell killing with myeloid reprogramming and immune activation, offering a unified strategy for metastatic TNBC.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    docetaxel • vadimezan (ASA404)
    2d
    Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study). (PubMed, JTO Clin Res Rep)
    A previous analysis of the RELAY phase 3 liquid biopsy addendum demonstrated suppressed EGFR-activating mutation allele count, increased total cell-free DNA (cfDNA) concentration, and shortened cfDNA fragment size with ramucirumab (RAM) plus erlotinib (ERL) versus placebo (PL) plus ERL in patients with EGFR-mutated NSCLC. This updated analysis revealed differences in total cfDNA concentration and T790M mutation rates between ex19del and L858R. RAM plus ERL may exhibit greater antitumor effects on L858R, supporting the favorable survival benefits observed previously in patients with a L858R.
    P3 data • Journal • Liquid biopsy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    erlotinib • Cyramza (ramucirumab)
    2d
    Scientific, regulatory, and practical considerations for bringing hepatocellular carcinoma biomarkers into clinical practice. (PubMed, JHEP Rep)
    Biomarkers like programmed death ligand-1 (PD-L1) expression, tumor mutational burden and microsatellite stability status have limited roles in HCC and only AFP is used in clinical practice for prediction of treatment benefit in patients recieving ramucirumab...In the European Union, the process involves EMA biomarker qualification procedures and conformity assessment under the In Vitro Diagnostic Regulation. Understanding these scientific, regulatory, and commercial considerations is essential for successfully translating HCC biomarker discoveries into clinical practice.
    Review • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression
    |
    Cyramza (ramucirumab)
    3d
    A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Ottimo Pharma Limited
    New P1/2 trial
    5d
    RAMOSE: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Xiuning Le | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab)
    5d
    A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=25, Not yet recruiting, Tongji Hospital
    New trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Jin Beixin (firsekibart)
    5d
    Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study (clinicaltrials.gov)
    P3, N=838, Active, not recruiting, SWOG Cancer Research Network | Trial primary completion date: Jan 2027 --> Nov 2025
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • HER-2 mutation • MET mutation
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)
    6d
    Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=500, Active, not recruiting, West China Hospital
    New trial
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    Sulanda (surufatinib)
    6d
    MA-GC-II-022: PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer (clinicaltrials.gov)
    P2, N=78, Recruiting, The First Affiliated Hospital of Zhengzhou University | N=36 --> 78
    Enrollment change
    |
    AiTan (rivoceranib) • capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554)
    7d
    Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors (2025-524111-37-00)
    P1/2, N=9, Not yet recruiting, Ottimo Pharma Limited
    New P1/2 trial
    8d
    RAMIRIS: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (clinicaltrials.gov)
    P2/3, N=429, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium
    9d
    A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jin Beixin (firsekibart) • Kineret (anakinra)